JBIO Stock Forecast: Jade Biosciences, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Jade Biosciences, Inc. is $46. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Jade Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (72): The shares have been drifting up relative to others.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
JBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on JBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Guggenheim | Maintains | Buy | $47 → $41 |
| 27 Oct 2026 | BTIG | Reiterates | Buy | $77 |
| 1 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $55 |
| 1 Oct 2026 | Wedbush | Reiterates | Outperform | $47 |
| 11 Aug 2026 | Wedbush | Maintains | Outperform | $45 → $47 |
| 10 Aug 2026 | BTIG | Maintains | Buy | $74 → $77 |
| 15 June 2026 | UBS | Initiates | Buy | $45 |
| 2 June 2026 | Wedbush | Maintains | Outperform | — |
| 1 June 2026 | BTIG | Maintains | Buy | — |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 May 2026 | BTIG | Reiterates | Buy | — |
| 11 May 2026 | Guggenheim | Maintains | Buy | — |
| 11 May 2026 | Wedbush | Maintains | Outperform | — |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Mar 2026 | BTIG | Maintains | Buy | — |
| 11 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 9 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 7 Jan 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Nov 2025 | Clear Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for JBIO.
This page is one stock. Monday covers all of them.
JBIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
JBIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Jade Biosciences, Inc. returned +33.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
JBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 40% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −38.3%
- Return on assets
- −36.4%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Jade Biosciences, Inc. has a market value of $1.1B and an enterprise value of $584.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$153.2M.
Free cash flow in the twelve months to 30 June 2026: −$123.6M.
Jade Biosciences, Inc. employs 55 people.
Data provided by Twelve Data
JBIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at JBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Jade Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about JBIO
What is the JBIO stock price forecast for 2026-2027?
The median 12-month analyst price target for Jade Biosciences, Inc. is $46, with estimates ranging from $40 to $77. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is JBIO stock a buy right now?
Of the 10 analysts covering Jade Biosciences, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jade Biosciences, Inc. 40 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank JBIO?
As at 21 Nov 2026, Jade Biosciences, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).
Will JBIO stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts is $46, and Ticker Nerd's factor model ranks Jade Biosciences, Inc. 40 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the JBIO stock forecast for 2030?
No analyst covering Jade Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $77 over the next 12 months.
How has JBIO stock performed over the past year?
Jade Biosciences, Inc. returned +33.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Jade Biosciences, Inc. do?
Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders.
About Jade Biosciences, Inc.
Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its current pipeline centers on antibody-based programs designed to target key immune pathways involved in conditions such as immunoglobulin A nephropathy and other inflammation-related disorders. The company’s lead candidate, JADE101, is being developed to inhibit APRIL, a protein linked to abnormal immune activity, while JADE201 and JADE301 are advancing through earlier-stage research for additional autoimmune indications. Jade Biosciences works as a development-focused biopharmaceutical company, relying on clinical research, preclinical testing, and collaboration agreements to advance its programs. Headquartered in Waltham, Massachusetts, the company serves the immunology and nephrology fields by pursuing targeted biologic therapies for patients with significant unmet medical needs.
CEO Mr. Tom Frohlich · 55 employees · United States · https://jadebiosciences.com